Frequently Asked Questions About MDS

Presented at: 
2012 AA&MDSIF Scientific Symposium
Presented by: 
Mikkael Sekeres, MD, MS
Date of Presentation: 
Thursday, March 22, 2012

Dr. Sekeres is an associate professor of medicine and director of the Leukemia Program at the Cleveland Clinic Lerner College of Medicine, and staff in the Department of Hematologic Oncology and Blood Disorders at The Cleveland Clinic in Ohio. He earned a medical degree and a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine. Dr. Sekeres completed his postgraduate training at Harvard University, finishing an internal medicine residency at Massachusetts General Hospital and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute in Boston. He is co-chair of the medical advisory board of the Aplastic Anemia & MDS International Foundation.

Dr. Sekeres answers these questions:

  1. What is MDS?
  2. Is MDS a cancer?
  3. What is hypocellular MDS?
  4. What do we know about the causes of MDS?
  5. How is MDS diagnosed?
  6. What is the difference between supportive care and active treatment?
  7. How do you decide on the best approach to treatment for a specific patient?
  8. How do you decide when to begin active treatment for a specific patient?
  9. How can a doctor and patient determine if a specific drug therapy is not working?
  10. What other options are available if the standard approach to therapy does not work?
  11. What are some of the short- and long-term side effects associated with the drug therapies used to treat patients with MDS?
  12. How do you recommend a patient deal with side effects of MDS treatment?
  13. What is iron overload and why can it be a problem for some MDS patients?
  14. What new treatments are on the horizon to treat MDS patients?